跳至主要内容
临床试验/ISRCTN65900535
ISRCTN65900535已完成未知

Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and above

eiden University Medical Center (LUMC) (The Netherlands)0 个研究点目标入组 50 人开始时间: 2006年12月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

2010 Results article in https://pubmed.ncbi.nlm.nih.gov/20473080/ (added 05/08/2021)

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients with depressive spectrum disorders (dysthymia, minor and major depression) using Standardised Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth edition (DSM-IV) disorders
  • 2. Age more than 60 years
  • 3. Late onset of depressive spectrum disorder (age more than 55 years)
  • 4. Resistant to at least one regular antidepressant drug, used for at least six weeks and in sufficient doses; or suffering from too many side effects of the antidepressant

排除标准

  • 1. Psychotic features
  • 2. Bipolar disorder
  • 3. Severe suicidal thoughts or actions
  • 4. Serious infectious diseases
  • 5. (Suspicion of) tuberculosis
  • 6. Serious cardiac failure
  • 7. Prior treatment with recombinant antibodies
  • 8. Allergy to infliximab
  • 9. Mini Mental State Examination (MMSE) less than or equal to 22/30
  • 10. Insufficient knowledge of the Dutch language

研究者

发起方
eiden University Medical Center (LUMC) (The Netherlands)

相似试验